Synribo (omacetaxine mepesuccinate) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has Philadelphia chromosome-positive chronic myeloid leukemia (CML)
• Patient meets one of the following (i or ii): i) Patient is T315I-positive; OR ii) Patient has tried at least two tyrosine kinase inhibitors indicated for use in CML (e.g., imatinib, Sprycel [dasatinib], Tasigna [nilotinib], Bosulif [bosutinib], Iclusig [ponatinib])
• Medication is prescribed by or in consultation with an oncologist

Approval duration

6 months